In a 23-year-old male with anxiety and depression who smokes and wishes to quit, is bupropion (Wellbutrin) an appropriate treatment choice?

Wellbutrin (Bupropion) for a 23-Year-Old Male with Anxiety, Depression, and Smoking

Bupropion is an excellent choice for this patient—it effectively treats depression, aids smoking cessation, and contrary to older concerns, recent high-quality evidence shows it does not worsen anxiety in most patients with comorbid depression and anxiety.

Why Bupropion Works Well Here

This patient presents with a dual indication scenario where bupropion addresses both conditions simultaneously:

For Smoking Cessation

Bupropion is a first-line pharmacotherapy for smoking cessation 1. The NCCN guidelines list it alongside combination NRT and varenicline as preferred primary therapy 1. Bupropion improves 12-month sustained abstinence rates and reduces withdrawal symptoms 2. The standard dosing is 150 mg once daily for 3 days, then 150 mg twice daily (maximum 300 mg/day), initiated 1-2 weeks before the quit date 1.

For Depression

Bupropion is FDA-approved for major depressive disorder and works through norepinephrine and dopamine reuptake inhibition rather than serotonergic mechanisms 3, 4. This makes it particularly useful when patients want to avoid sexual side effects common with SSRIs 5.

The Anxiety Question: Critical Evidence

The concern about bupropion worsening anxiety is largely outdated. Here's what the most recent, high-quality evidence shows:

• A 2025 systematic review found that bupropion generally improves anxiety symptoms in patients with MDD and comorbid anxiety 5. None of the included studies (n ≈ 3700 patients) reported clear signals of anxiety worsening on validated anxiety measures.

• A 2025 review specifically examining bupropion and anxiety concluded that clinical trials show bupropion may reduce anxiety symptoms in depressed patients, with comparable efficacy to SSRIs/SNRIs in mild to moderate anxiety 4.

• The landmark 2016 EAGLES trial (n=8,058) found no significant increase in neuropsychiatric adverse events with bupropion compared to nicotine patches or placebo in patients both with and without psychiatric disorders 1. This was a rigorous multicenter RCT that specifically examined neuropsychiatric safety.

Important Nuance

While bupropion's stimulating properties can provoke anxiety at higher doses in some individuals 4, this is manageable through:

• Starting at 150 mg once daily and titrating slowly
• Monitoring for anxiogenic symptoms during the first 2-4 weeks
• Avoiding doses above 300 mg/day

SSRIs may have a modest advantage only in patients with severe, highly anxious depression 5, but this patient is 23 years old and wants to quit smoking—bupropion's dual benefit makes it the superior choice.

Safety Monitoring Requirements

Black Box Warnings (FDA Label)

The FDA label carries warnings about neuropsychiatric symptoms and suicidal ideation 6. However, these warnings apply to all antidepressants and smoking cessation medications—they are not unique to bupropion. The EAGLES trial data provides reassurance that actual risk is not elevated compared to other options 1.

Close monitoring is essential during the first 4-8 weeks for:

• New or worsening depression
• Suicidal thoughts or behavior
• Anxiety, agitation, or panic attacks
• Insomnia (common but manageable)
• Hostility or aggression

Contraindications to Screen For

Do not use bupropion if the patient has 1:

• History of seizures or seizure disorder (risk ~1 in 1000) 2
• Current or prior diagnosis of bulimia or anorexia nervosa
• Abrupt discontinuation of alcohol or benzodiazepines (lowers seizure threshold)
• Taking MAO inhibitors
• Closed-angle glaucoma

Additional Monitoring

• Blood pressure: Can cause hypertension, especially when combined with nicotine replacement 6
• Manic symptoms: Screen for bipolar disorder history before initiating 6

Practical Implementation Algorithm

Week -2 to -1 (Before Quit Date):

1. Start bupropion 150 mg once daily in the morning
2. Assess tolerance, anxiety levels, and sleep
3. Provide behavioral counseling for smoking cessation

Week 0 (Quit Date):

1. Increase to 150 mg twice daily (morning and early afternoon to avoid insomnia)
2. Set quit date
3. Consider adding short-acting NRT (gum/lozenge) for breakthrough cravings 1

Weeks 1-12:

1. Continue bupropion 300 mg/day
2. Weekly check-ins for first month, then monthly
3. Monitor mood, anxiety, smoking status, and side effects

After 12 Weeks:

1. If abstinent and depression improved: Consider continuing 6-12 months 1, 7
2. If still smoking: Switch to varenicline or add combination NRT 1
3. If anxiety worsens significantly: Reassess diagnosis and consider SSRI/SNRI

Common Pitfalls to Avoid

1. Underdosing for smoking cessation: The effective dose is 300 mg/day—don't stop at 150 mg 1

2. Starting too close to quit date: Begin 1-2 weeks before to achieve steady-state levels 1

3. Dismissing bupropion due to outdated anxiety concerns: Recent evidence contradicts this 4, 5

4. Not combining with behavioral support: Pharmacotherapy alone is less effective 2

5. Stopping too soon: Treatment should continue 7-12 weeks minimum, potentially longer for depression 1

6. Missing seizure risk factors: Always screen for eating disorders, alcohol abuse, and seizure history 6

Alternative Considerations

If anxiety is severe and predominant (not the case described here), consider:

• SSRI/SNRI + varenicline for smoking cessation
• SSRI/SNRI + NRT combination

If bupropion fails or is not tolerated:

• Varenicline (more effective for smoking cessation but no antidepressant effect) 1, 7
• SSRI/SNRI + combination NRT 1

For this specific 23-year-old patient with depression, anxiety, and desire to quit smoking, bupropion represents an evidence-based, efficient approach that addresses both conditions with a single medication, provided proper screening and monitoring are in place.